Antibody therapy Mim8 was found to be safe and effective for controlling bleeds in children with hemophilia A in a Phase 3 ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Hemlibra was found to ease pain and improve quality of life for hemophilia A patients, even those with long-term joint damage, per a study.

and the haemophilia treatment Hemlibra (emicizumab-kxwh). Combined, these products pulled in CHF 16.9bn ($18.6bn), marking a CHF 3.3bn ($3.6bn) increase over 2023. Vabsymo, launched in early 2022 ...

Overseas sales rose for hemophilia drug Hemlibra through Swiss parent Roche. The drugmaker had forecast a drop in revenue from 2023, when it received a boost from supplying COVID-19 treatment ...

Hemlibra patient share in the U.S./EU now reaching 42%, and we are now also looking forward to the Phase III enabling readout of NXT007, which is the next-generation Hemlibra. In neurology ...

RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.